title: Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
abstract: OBJECTIVE
  To determine incidence of non-AIDS-defining cancers (NADC) in HIV-infected patients before (P1) and during (P2) the use of highly active antiretroviral therapy (HAART) relative to that observed in the French general population (FGP) of the same age and sex.
  
  
  METHODS
  Sex- and age-adjusted NADC standardized incidence ratios (SIR), with FGP as reference, were estimated in 1992 to 1995 (P1) and in 1996 to 1999 (P2) in a French Hospital Database on HIV prospective hospital cohort study.
  
  
  RESULTS
  NADCs were diagnosed in 260 patients during P1 and 391 patients during P2 among the 77,025 patients included in the database between January 1, 1992, and December 31, 1999. Estimated incidence of all cancers was higher in HIV-infected men than in FGP during both periods (P1 SIR = 2.36 and P2 SIR = 1.91). No excess of cancers was observed among HIV-infected women in either period. Incidence of all cancers did not change from P1 to P2 in either sex (SIR = 0.96 for men and 1.00 for women). In contrast, incidence of Hodgkin's disease (HD) was higher than in FGP in both sexes and both periods and increased in P2 as compared with P1; incidence of lung cancer was higher in both sexes during P2.
  
  
  CONCLUSIONS
  Relative to FGP, the overall incidence of NADCs was increased in HIV-infected men but not in women and did not differ between P1 and P2. Only HD was much more common in HIV infection, and the potential role of HAART on HD cannot be excluded.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale Equipe Mixte 0214, 56 Boulevard Vincent Auriol, BP 335, 75625 Paris Cedex 13, France.
authors.forename: Magid
authors.initials: M
authors.lastname: Herida
authors.forename: Murielle
authors.initials: M
authors.lastname: Mary-Krause
authors.forename: Régis
authors.initials: R
authors.lastname: Kaphan
authors.forename: Jacques
authors.initials: J
authors.lastname: Cadranel
authors.forename: Isabelle
authors.initials: I
authors.lastname: Poizot-Martin
authors.forename: Christian
authors.initials: C
authors.lastname: Rabaud
authors.forename: Nathalie
authors.initials: N
authors.lastname: Plaisance
authors.forename: Hervé
authors.initials: H
authors.lastname: Tissot-Dupont
authors.forename: François
authors.initials: F
authors.lastname: Boue
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Lang
authors.forename: Dominique
authors.initials: D
authors.lastname: Costagliola
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000453:epidemiology; D011446:Prospective Studies